[go: up one dir, main page]

US5376379A - Liposomes of thermal waters stabilized in a DNA gel - Google Patents

Liposomes of thermal waters stabilized in a DNA gel Download PDF

Info

Publication number
US5376379A
US5376379A US08/066,111 US6611193A US5376379A US 5376379 A US5376379 A US 5376379A US 6611193 A US6611193 A US 6611193A US 5376379 A US5376379 A US 5376379A
Authority
US
United States
Prior art keywords
dna
liposomes
composition according
active ingredient
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/066,111
Inventor
Pierre Fabre
Henri Cousse
Gilbert Mouzin
Marie-Therese Trebosc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Dermo Cosmetique SA
Original Assignee
Pierre Fabre Dermo Cosmetique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9401303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US5376379(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre Dermo Cosmetique SA filed Critical Pierre Fabre Dermo Cosmetique SA
Assigned to PIERRE FABRE COSMETIQUE reassignment PIERRE FABRE COSMETIQUE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COUSSE, HENRI, FABRE, PIERRE, MOUZIN, GILBERT, TREBOSC, MARIE-THERESE
Application granted granted Critical
Publication of US5376379A publication Critical patent/US5376379A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/08—Mineral waters; Sea water
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/965—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of inanimate origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Definitions

  • the present invention relates to compositions based on thermal water containing liposomes of thermal water stabilized in a DNA gel, which are useful especially in dermatology and in cosmetology.
  • Liposomes are microvesicles consisting of one or more lipid double layers delimiting a central aqueous space and, in the case of multilamellar liposomes, an aqueous behavior between two double layers.
  • These structures consist of phospholipids to which sterols such as cholesterol are frequently added in order to increase the stability.
  • Liposomes may be classified according to their size and their uni- or multilammelar character.
  • microvesicles are capable of interacting with cells whose membranes are identical in nature to that of the liposome.
  • EGF Extracellular Growth Factor
  • superoxide dismutases are thought locally to have an anti-inflammatory action.
  • liposome vesicles are too fragile in the formulations used and they are often destroyed before reaching their target.
  • the principal gelling agents used are: gelatin, carboxyvinyl polymers, methacrylic polymers, polydimethyl-siloxane copolymers and, more recently, collagen.
  • the stabilization of the liposomes in an aqueous gel with the gelling agents currently used does not make it possible to obtain a stability of a formula greater than 3 months at a temperature of 40° C.
  • the present invention makes it possible to overcome this major disadvantage by stabilizing the liposomes in a deoxyribonucleic acid gel.
  • the DNA will be DNA which is highly polymerized according to processes known to persons skilled in the art (hereinafter "HP DNA”) and which is available commercially.
  • HP DNA DNA which is highly polymerized according to processes known to persons skilled in the art
  • DNA having a molecular mass of between 500,000 and 1.5 million, preferably between 800,000 and 1.2 million.
  • composition according to the invention advantageously contains 0.1 to 10% by weight of DNA and more particularly 0.5 to 5%.
  • thermal water and more particularly AVENE water or CAUTERETS water, is incorporated into the liposomes.
  • AVENE water has therapeutic qualities which are useful in the treatment of eczemas, pruritus, psoriasis, retardation of cicatrization, burns.
  • Basic studies have also supported the effectiveness of AVENE WATER.
  • AVENE WATER exerts an inhibitory effect on the degranulation of human basophiles. It also inhibits the migration of polynuclear cells which have an important role in skin inflammation.
  • Sulfurated CAUTERETS water in the form of liposomes, is of interest in dermatology and more particularly in the following treatments: psoriasis, eczemas, acne, pruritus, seborrhoea, alopecia.
  • composition of AVENE WATER is as follows:
  • composition of CAUTERETS water is as follows:
  • any other thermal water of therapeutic and/or cosmetic interest may also be microencapsulated so as to allow a targeted penetration of these waters into the epidermis and the dermis.
  • the composition optionally contains, in addition, an associated active ingredient such as
  • an antibacterial agent and more particularly phenonip, EDTA, benzoic acid, butyl para hydroxybenzoate, sorbic acid,
  • vitamin E an associated vitamin ingredient such as vitamin E, vitamin C,
  • an oil such as borage oil or argan oil.
  • This associated active ingredient will thus be present in particular in an amount of 0 of 5% and more often 0.1 to 3% by weight of the composition.
  • composition according to the present invention advantageously contains 0.1 to 10% by weight of lipids entering into the constitution of the liposomes and more particularly 0.5 to 5%, the (lipid)/(liposome-encapsulated thermal water) weight ratio is about 1/3.
  • the liposomes used in the present invention are of the multilamellar type, prepared according to French Patent 2,634,375.
  • the liposome gels are prepared in the following manner:
  • a lipid phase consisting essentially of a solution of amphiphilic lipids and optionally a said associated active ingredient of lipophilic nature is prepared in an organic solvent and more particularly ethanol.
  • This phase is then added, with gentle stirring, to a solution of thermal water optionally containing a said associated ingredient of hydrophilic nature.
  • amphiphilic lipids may be glycolipids, phosphoamino lipids and especially phospholipids, for example lecithins (of egg, soya bean, and the like).
  • the solvent is preferably an alcohol which is miscible with water in all proportions, especially ethanol.
  • amphiphilic lipids may contain, in addition, a substance of lipophilic nature designed to modify the physical characteristics (electric charge, rigidity) or the chemical characteristics of the wall, such as cholesterol, stearylamine, phosphatidic acid and the like.
  • the concentration of lipids in the solvent may be 0.1 to 10% by weight, preferably 1 to 5% by weight.
  • the volume of solvent used for phase (1) is between 30 and 100%; for example about 50%, of the volume of water of phase (2), in order to obtain liposomes of small size (especially from 100 to 300 nm).
  • the invention makes it possible to obtain medicinal products, especially in injectable form, and cosmetic products which are very stable.
  • the invention makes it possible to obtain liposomes of thermal water which are perfectly stable in a gel.
  • formulations obtained according to the present invention may be used in dermocosmetology especially by topical application when the composition contains a vehicle for topical application, it may be a gel packaged in a tube or in a pump-based mechanical system, or a spray composition delivered in the form of a gel.
  • the organic phase I is introduced into the aqueous phase II in thin jets by means of a Kremlin apparatus and a peristaltic pump.
  • Hp DNA marketed by the company JAVERNECH.
  • Hp DNA marketed by the company JAVERNECH.
  • the dissolution is carried out slowly at room temperature. After stirring for 1 hour, a stabilized formulation is obtained containing 2% Hp DNA gel and 2% liposomes.
  • the quantity (by weight) of thermal water encapsulated in the liposomes is of the order of 3 times that of the lipids which constitute the liposomes.
  • the stability study was carried out at 40° C. on formulations containing 2% liposomes of Avene thermal water.
  • the visualization was performed using an electron microscope, this visualization is carried out each month after subjecting the liposomes to negative staining by means of a 2% solution of sodium phosphotungstate.
  • the photographic examinations show that the liposomes are correctly dispersed in an HP DNA lattice without modification of their shape and their size and confirms the surprising stability of the liposomes in base formulation.
  • An H.P. DNA level of 0.5 to 2% makes it possible to stabilize the liposomes for 24 months, whereas with the conventional gelling agents of the Carbopol and/or Collagen type, the stability of the liposomal membranes is maintained for a maximum of 6 months.
  • This stability may be explained by the crosslinkage of the H.P. DNA fibers in aqueous medium which allows the dispersion of the liposomes and prevents the fusion of the lipid vesicles.
  • the vectorization of mineral water in liposomal form according to the invention makes it possible, surprisingly, to potentiate the pharmacological and clinical activity of this water.
  • the leucocytic pellet contains 1500 to 3000 basophiles/mm 3 .
  • the leucocytes obtained are then suspended in an inorganic buffer and then centrifuged.
  • the sensitizing antigen is then diluted in RPMI 1640 (flows Labo) (7 5-fold serial dilutions) starting with a concentration of for example 10-3 in the case of glycerinated extracts.
  • the cell-antigen mixture is incubated for 15 min at 37° C. and then stained with toluidine blue.
  • the non-degranulated basophiles are then counted in Malassez or Fuchs-Rosenthal hemocytoniters .
  • the table below shows the results expressed in maximum percentage of degranulation for 15 degranulation tests in the presence of various pneumallergens.
  • the average percentage of degranulation for the 15 experiments is 57.1% for the distilled water controls, 29.3% for Avene water and 14.1% for the tests carried out with stabilized liposomes. (This difference is highly significant p ⁇ 0.01).
  • the vectorization of Avene water by the liposomes allows a 100% potentiation of the inhibitory effect of the degranulation of the basophiles.
  • SLS Lauryl Sulfate
  • the three products to be studied are used as solvent for SLS in order to prepare solutions at the same concentration as the control SLS solution which constitutes the model of irritation. They are applied together with the control on the occlusive patch test, for 24 hours.
  • the evaluation of the intensity of skin irritation is carried out by measuring the variations in skin blood flow by Doppler Laser Velocimetry (DLV).
  • DLV Doppler Laser Velocimetry
  • Three SLS solutions at 0.75% are prepared using the products to be studied (a-b-c).
  • the control SLS solution and the a, b and c solutions are applied in a random manner in an amount of 65 ⁇ l/cm 3 on a disk of filter paper.
  • An occlusive dressing is then maintained for 24 hours. After removing the dressings, the skin is left in the open air for 30 min before starting the measurements so as to eliminate any possible effect of the occlusion.
  • the measurement of the skin blood flow is carried out by recording the DLV for 10 min on each area, on the one hand, before application of the patches, so as to obtain the physiological baseline and, on the other hand, 30 min after removing the patches.
  • AUC SLS area under the curve for the solution of SLS alone
  • AUC p area under the curve for the solutions of the products a, b and c

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to compositions based on thermal water containing liposomes of thermal water stabilized in a deoxyribonucleic acid (DNA) gel and a process for preparing thereof. The composition is useful in dermatology and cosmetology.

Description

The present invention relates to compositions based on thermal water containing liposomes of thermal water stabilized in a DNA gel, which are useful especially in dermatology and in cosmetology. Liposomes are microvesicles consisting of one or more lipid double layers delimiting a central aqueous space and, in the case of multilamellar liposomes, an aqueous behavior between two double layers.
These structures consist of phospholipids to which sterols such as cholesterol are frequently added in order to increase the stability.
Liposomes may be classified according to their size and their uni- or multilammelar character.
______________________________________                                    
MLV (multilammelar vesicles):                                             
                      diameter 100 to                                     
                      5000 nm (several                                    
                      double layers)                                      
LUV (large unilammelar                                                    
                      diameter 200 to                                     
vesicles):            2000 nm (1 double                                   
                      layer)                                              
SUV (small unilammelar                                                    
                      diameter 20 to                                      
vesicles):            80 nm (1 double                                     
                      layer)                                              
______________________________________
Techniques enabling large quantities of liposomes to be obtained have been developed in industry (ultra-dispersion, sonication, lipopred.) ref. PUISIEUX F., DELATTRE J.--Les liposomes. Application therapeutiques, Technique et Documentation, Lavoisier Paris, 1985.
These microvesicles are capable of interacting with cells whose membranes are identical in nature to that of the liposome.
Dermatology and cosmetology constitute promising sectors for the exploitation of liposomes.
The principal studies relating to the skin relate to the liposomes of corticoids. It would appear that the microencapsulation of corticoids reduces the percutaneous penetration of the product and increases its concentration at local sites : epidermis and dermis. Ref. WOHLRAB W., LASCH J.--Penetration Kinetics of liposomal hydrocortisone in human skin. Dermatologica 174, 18-22, 1987.
Other substances have been incorporated but the studies are too fragmented to be generalized: EGF (Epidermal Growth Factor) is thought to promote the cicatrization of wounds : superoxide dismutases are thought locally to have an anti-inflammatory action. Unfortunately, the liposome vesicles are too fragile in the formulations used and they are often destroyed before reaching their target.
Many others have mentioned the use of gelling agents to stabilize liposomal vesicles in the form of an aqueous gel.
The principal gelling agents used are: gelatin, carboxyvinyl polymers, methacrylic polymers, polydimethyl-siloxane copolymers and, more recently, collagen.
The stabilization of the liposomes in an aqueous gel with the gelling agents currently used does not make it possible to obtain a stability of a formula greater than 3 months at a temperature of 40° C.
The present invention makes it possible to overcome this major disadvantage by stabilizing the liposomes in a deoxyribonucleic acid gel.
According to the invention, the DNA will be DNA which is highly polymerized according to processes known to persons skilled in the art (hereinafter "HP DNA") and which is available commercially.
There may be mentioned in particular DNA having a molecular mass of between 500,000 and 1.5 million, preferably between 800,000 and 1.2 million.
The composition according to the invention advantageously contains 0.1 to 10% by weight of DNA and more particularly 0.5 to 5%.
According to the invention, thermal water, and more particularly AVENE water or CAUTERETS water, is incorporated into the liposomes. AVENE water has therapeutic qualities which are useful in the treatment of eczemas, pruritus, psoriasis, retardation of cicatrization, burns. Basic studies have also supported the effectiveness of AVENE WATER. Thus, several series of studies have made it possible to demonstrate that AVENE WATER exerts an inhibitory effect on the degranulation of human basophiles. It also inhibits the migration of polynuclear cells which have an important role in skin inflammation.
Sulfurated CAUTERETS water, in the form of liposomes, is of interest in dermatology and more particularly in the following treatments: psoriasis, eczemas, acne, pruritus, seborrhoea, alopecia.
The composition of AVENE WATER is as follows:
______________________________________                                    
                mg/l                                                      
______________________________________                                    
ANION                                                                     
HCO.sub.3.sup.-  (bicarbonates)                                           
                  218.4                                                   
Cl.sup.-  (chlorides)                                                     
                  5.8                                                     
SO.sub.4 (sulfates)                                                       
                  12.4                                                    
NO.sub.3 (nitrates)                                                       
                  1.1                                                     
NO.sub.2 (nitrites)                                                       
                  <0.02                                                   
F.sup.-  (fluorides                                                       
                   0.12                                                   
PO.sub.4 (phosphates)                                                     
                  <0.1                                                    
Br.sup.-  (bromides)                                                      
                  <0.1                                                    
CATIONS                                                                   
Ca.sup.++  (calcium)                                                      
                  40.8                                                    
Mg.sup.++  (magnesium)                                                    
                  22.7                                                    
K.sup.+  (potassium)                                                      
                  1.0                                                     
Na.sup.+  (sodium)                                                        
                  4.8                                                     
Li.sup.+  (lithium)                                                       
                  <0.1                                                    
Fe.sup.++  (iron) <0.01                                                   
Mn.sup.++  (manganese)                                                    
                   <0.0005                                                
Sr.sup.++  (strontium)                                                    
                   0.13                                                   
______________________________________
The composition of CAUTERETS water is as follows:
______________________________________                                    
               mg/l                                                       
______________________________________                                    
ANION                                                                     
HCO.sub.3 (bicarbonates)                                                  
                 25                                                       
CO.sub.3 (carbonates)                                                     
                 23.4                                                     
H.sub.3 SiO.sub.4.sup.-  (silicates)                                      
                 32.8                                                     
Cl.sup.-  (chlorides)                                                     
                 45                                                       
SO.sub.4.sup.2-  (sulfates)                                               
                 31.5                                                     
NO.sub.2.sup.-  (nitrites)                                                
                 --                                                       
NO.sub.3.sup.-  (nitrates)                                                
                 --                                                       
PO.sub.4.sup.3-  (phosphates)                                             
                 --                                                       
F.sup.-  (fluorides)                                                      
                  2.2                                                     
HS.sup.-  (sulfides)                                                      
                 trace amounts                                            
SO.sub.3.sup.2-  (sulfites)                                               
                 trace amounts                                            
S.sub.2 O.sub.3.sup.2-  (thiosulfate)                                     
                  5.6                                                     
CATIONS                                                                   
Ca.sup.2+  (calcium)                                                      
                 5                                                        
Mg.sup.2+  (magnesium)                                                    
                  0.12                                                    
Na.sup.+  (sodium)                                                        
                 63.6                                                     
K.sup.+  (potassium)                                                      
                  1.8                                                     
NH.sub.4.sup.+  (ammonium)                                                
Mn.sup.2+  (manganese)                                                    
Al.sup.3+  (aluminum)                                                     
Zn.sup.2+  (zinc)                                                         
Cu.sup.2+  (copper)                                                       
Li.sup.+  (lithium)                                                       
                  0.18                                                    
______________________________________
Naturally, according to the present invention, any other thermal water of therapeutic and/or cosmetic interest may also be microencapsulated so as to allow a targeted penetration of these waters into the epidermis and the dermis.
According to an additional characteristic of the present invention, the composition optionally contains, in addition, an associated active ingredient such as
an antibacterial agent and more particularly phenonip, EDTA, benzoic acid, butyl para hydroxybenzoate, sorbic acid,
an associated vitamin ingredient such as vitamin E, vitamin C,
or alternatively, an oil such as borage oil or argan oil.
Naturally, the above list is not limiting.
This associated active ingredient will thus be present in particular in an amount of 0 of 5% and more often 0.1 to 3% by weight of the composition.
The composition according to the present invention advantageously contains 0.1 to 10% by weight of lipids entering into the constitution of the liposomes and more particularly 0.5 to 5%, the (lipid)/(liposome-encapsulated thermal water) weight ratio is about 1/3.
In one embodiment, the liposomes used in the present invention are of the multilamellar type, prepared according to French Patent 2,634,375.
In this particular embodiment, the liposome gels are prepared in the following manner:
a) liposomes
A lipid phase consisting essentially of a solution of amphiphilic lipids and optionally a said associated active ingredient of lipophilic nature is prepared in an organic solvent and more particularly ethanol.
This phase is then added, with gentle stirring, to a solution of thermal water optionally containing a said associated ingredient of hydrophilic nature.
After evaporation under reduced pressure, a suspension of desired liposome concentration is obtained.
The amphiphilic lipids may be glycolipids, phosphoamino lipids and especially phospholipids, for example lecithins (of egg, soya bean, and the like).
The solvent is preferably an alcohol which is miscible with water in all proportions, especially ethanol.
The solution of amphiphilic lipids may contain, in addition, a substance of lipophilic nature designed to modify the physical characteristics (electric charge, rigidity) or the chemical characteristics of the wall, such as cholesterol, stearylamine, phosphatidic acid and the like.
The concentration of lipids in the solvent may be 0.1 to 10% by weight, preferably 1 to 5% by weight.
It is advantageous that the volume of solvent used for phase (1) is between 30 and 100%; for example about 50%, of the volume of water of phase (2), in order to obtain liposomes of small size (especially from 100 to 300 nm).
Thus, the invention makes it possible to obtain medicinal products, especially in injectable form, and cosmetic products which are very stable.
b) preparation of the liposome gel
To the above suspension are added, with gentle stirring, DNA (especially HP DNA) as well as, optionally, preservatives and perfumes.
The invention makes it possible to obtain liposomes of thermal water which are perfectly stable in a gel.
These formulations obtained according to the present invention may be used in dermocosmetology especially by topical application when the composition contains a vehicle for topical application, it may be a gel packaged in a tube or in a pump-based mechanical system, or a spray composition delivered in the form of a gel.
The following examples are intended to illustrate the invention without, however, being of a limiting nature.
EXAMPLE 1 Preparation of a 5 kg batch of liposomes of AVENE water containing 2% lipids. Raw material 
______________________________________                                    
1 - organic phase                                                         
phospholipid (Lipoid 80)o [sic]                                           
                    100        g                                          
SEPPIC                                                                    
Cholesterol BP      15         g                                          
Ethanol 95%         2.5        liters                                     
2 - aqueous phase                                                         
AVENE water         5          liters                                     
EDTA, disodium      10         g                                          
______________________________________
Procedure
1--Preparation of the organic phase I
Into 2.5 liters of ethanol are introduced, with vigorous stirring at room temperature, 100 g of phospholipid, 10 g of cholesterol and 10 g of phenonip. The stirring is continued for 1/2 hour until dissolution and production of a pale yellow homogeneous phase.
2--Preparation of the aqueous phase
Into 5 liters of Avene water are introduced, with stirring, 10 g of disodium EDTA.
3--Preparation of the liposomes
The organic phase I is introduced into the aqueous phase II in thin jets by means of a Kremlin apparatus and a peristaltic pump.
The addition, with vigorous stirring, by means of a Rayneri apparatus lasts for 15 min. The organic phase should be introduced outside the stirring cone. A milky phase is formed.
2.7 liters (ethanol+water) are evaporated under reduced pressure. The temperature of the water bath is 50° C. A 4.8-liter milky solution is obtained containing 2% lipids which is adjusted to 5 liters with AVENE water.
EXAMPLE 2 Preparation of the composition of liposomes of thermal water stabilized by an HP DNA gel.
To the above milky solution containing 2% lipids are added, with gentle stirring and in small fractions, 100 g of Hp DNA (marketed by the company JAVERNECH). The dissolution is carried out slowly at room temperature. After stirring for 1 hour, a stabilized formulation is obtained containing 2% Hp DNA gel and 2% liposomes.
EXAMPLE 3 Formulations
In the formulations below, the quantity (by weight) of thermal water encapsulated in the liposomes is of the order of 3 times that of the lipids which constitute the liposomes.
______________________________________                                    
FORMULATION 1:                                                            
Lipids               2%                                                   
HP DNA               2%                                                   
Phenonip             0.5%                                                 
EDTA                 0.2%                                                 
Avene water q.s.     100                                                  
FORMULATION 2:                                                            
Lipids               2%                                                   
HP DNA               0.5%                                                 
Phenonip             0.5%                                                 
EDTA                 0.2%                                                 
Avene water q.s.     100                                                  
FORMULATION 3:                                                            
Lipids               2%                                                   
HP DNA               0.1%                                                 
Phenonip             0.5%                                                 
EDTA                 0.2%                                                 
Avene water q.s.     100                                                  
FORMULATION 4:                                                            
Lipids               0.5%                                                 
HP DNA               0.2%                                                 
Butyl para-hydroxybenzoate                                                
                     0.2%                                                 
Floral water         1%                                                   
Avene water q.s.     100                                                  
FORMULATION 5:                                                            
Lipids               2%                                                   
HP DNA               0.5%                                                 
Sorbic acid          0.3%                                                 
Cauterets water q.s. 100                                                  
FORMULATION 6:                                                            
Lipids               1%                                                   
HP DNA               0.5%                                                 
Vitamin C            1%                                                   
Phenonip             0.5%                                                 
Floral water         1%                                                   
Cauterets water q.s. 100                                                  
FORMULATION 7:                                                            
Lipids               2%                                                   
HP DNA               0.5%                                                 
Ginkgo extract       1%                                                   
Phenonip             0.5%                                                 
Floral water         1%                                                   
Thermal water q.s.   100                                                  
FORMULATION 8:                                                            
Lipids               0.1%                                                 
HP DNA               0.5%                                                 
Borage oil           1%                                                   
Phenonip             1%                                                   
Thermal water q.s.   100                                                  
FORMULATION 9:                                                            
Lipids               10%                                                  
HP DNA               5%                                                   
Vitamin E            0.5%                                                 
Phenonip             1%                                                   
Thermal water q.s.   100                                                  
______________________________________
EXAMPLE 4 Stability study
The stability study was carried out at 40° C. on formulations containing 2% liposomes of Avene thermal water.
The visualization was performed using an electron microscope, this visualization is carried out each month after subjecting the liposomes to negative staining by means of a 2% solution of sodium phosphotungstate.
The results of this study are summarized in the following table:
______________________________________                                    
       Time/month                                                         
gelling agent                                                             
         1     2     3   4   5   6   7   8   9   10  11                   
                             12                                           
______________________________________                                    
Gelatin 5%                                                                
         +     ±  -                                                    
                             Carbopol 941 + + ± -                      
                             (0.5%)                                       
                             Carbopol 910 + + ± -                      
                             (0.5%)                                       
                             Endispert HV + + + ± -                    
                             (0.5%)                                       
                             Endispert + + ± -                         
                             MV (0.5%)                                    
                             Dimethycone + + + ± -                     
                             copolyol                                     
                             (2%)                                         
                             Collagen + + + ± -                        
                             (5%)                                         
                             HP DNA + + + + + + + + ± +                
                             (0.1%)                                       
                             HP DNA + + + + + + + + + + + +               
                             (0.5%)                                       
                             HP DNA + + + + + + + + + + + +               
                             (2%)                                         
______________________________________                                    
 + = Good stability (liposome 300 + 30 nm)                                
 + = Increase in size of the liposomes (by membrane fusion)               
 - = Phase separation (instability of the formula).
The photographic examinations show that the liposomes are correctly dispersed in an HP DNA lattice without modification of their shape and their size and confirms the surprising stability of the liposomes in base formulation.
From the other experiments carried out, the result is reached that the presence of DNA according to the invention makes it possible to obtain a remarkable stabilization of the liposomes of mineral water according to the invention during their preparation as well as in the galenical formulations.
An H.P. DNA level of 0.5 to 2% makes it possible to stabilize the liposomes for 24 months, whereas with the conventional gelling agents of the Carbopol and/or Collagen type, the stability of the liposomal membranes is maintained for a maximum of 6 months.
This stability may be explained by the crosslinkage of the H.P. DNA fibers in aqueous medium which allows the dispersion of the liposomes and prevents the fusion of the lipid vesicles.
EXAMPLE 5 Pharmaceutical and chemical activity
The vectorization of mineral water in liposomal form according to the invention makes it possible, surprisingly, to potentiate the pharmacological and clinical activity of this water.
The results obtained are summarized below.
1. Inhibition of the degranulation of human basophiles
The degranulation of human basophiles is examined according to the following procedure:
Production of basophiles sensitized to a given antigen from samples from allergic patients or after passive sensitization of basophiles of donors with a serum rich in specific IgE antibodies.
When the sensitized basophiles are obtained from allergic patients, it is necessary to carry out an enrichment by mere sedimentation at 1 g and centrifugation of the leucocyte-rich plasma. The leucocytic pellet contains 1500 to 3000 basophiles/mm3.
The leucocytes obtained are then suspended in an inorganic buffer and then centrifuged. The sensitizing antigen is then diluted in RPMI 1640 (flows Labo) (7 5-fold serial dilutions) starting with a concentration of for example 10-3 in the case of glycerinated extracts.
To study the vectorization of Avene water on this sensitizing basophile-allergen, pure water and distilled water are placed in contact with an aliquot of the cell pellet and incubated for 30 min at 25° C. After this incubation time, the cell suspension is mixed in equal volumes with the dilutions of the antigen, plus a control without antigen.
The cell-antigen mixture is incubated for 15 min at 37° C. and then stained with toluidine blue.
The non-degranulated basophiles are then counted in Malassez or Fuchs-Rosenthal hemocytoniters .
Results
The table below shows the results expressed in maximum percentage of degranulation for 15 degranulation tests in the presence of various pneumallergens. The average percentage of degranulation for the 15 experiments is 57.1% for the distilled water controls, 29.3% for Avene water and 14.1% for the tests carried out with stabilized liposomes. (This difference is highly significant p<0.01).
______________________________________                                    
                         Avene water                                      
                         liposomes H.P.                                   
Distilled water                                                           
              Avene Water                                                 
                         DNA (5%)                                         
______________________________________                                    
57.1%         29.3%      14.1%                                            
______________________________________
Conclusion
The vectorization of Avene water by the liposomes allows a 100% potentiation of the inhibitory effect of the degranulation of the basophiles.
2. Pharmacoclinical study
A potentiation of the anti-irritant activity in man was studied using a model of skin irritation caused by Sodium Lauryl Sulfate (SLS).
Products tested
(a) Distilled water
(b) Avene water
(c) Avene water (liposomes H.P. DNA--5%)
The three products to be studied are used as solvent for SLS in order to prepare solutions at the same concentration as the control SLS solution which constitutes the model of irritation. They are applied together with the control on the occlusive patch test, for 24 hours.
The evaluation of the intensity of skin irritation is carried out by measuring the variations in skin blood flow by Doppler Laser Velocimetry (DLV).
Procedure (number of subjects: 20)
Three SLS solutions at 0.75% are prepared using the products to be studied (a-b-c). The control SLS solution and the a, b and c solutions are applied in a random manner in an amount of 65 μl/cm3 on a disk of filter paper.
An occlusive dressing is then maintained for 24 hours. After removing the dressings, the skin is left in the open air for 30 min before starting the measurements so as to eliminate any possible effect of the occlusion.
The measurement of the skin blood flow is carried out by recording the DLV for 10 min on each area, on the one hand, before application of the patches, so as to obtain the physiological baseline and, on the other hand, 30 min after removing the patches.
The results are expressed by the mean of the area under the curve.
The percentage inhibition of inflammation by SLS is calculated by means of the following formula: ##EQU1## AUC SLS=area under the curve for the solution of SLS alone AUC p=area under the curve for the solutions of the products a, b and c
To determine whether the activity of the products studied is significant, a statistical study using the paired Student's t test is carried out on the results obtained.
Results
Percentage inhibition of the irritation induced by SLS
______________________________________                                    
a             b        c                                                  
______________________________________                                    
14 NS         39.8 (S) 82.2 (S)                                           
______________________________________
The clinical study confirms the very clear potentiation (>100%) of the anti-inflammatory activity of Avene water vectorized by liposomes.

Claims (13)

We claim:
1. A composition based on thermal water comprising liposomes encapsulating thermal water and said liposomes stabilized in a deoxyribonucleic acid (DNA) gel.
2. The composition according to claim 1 wherein the deoxyribonucleic acid is highly polymerized (HP DNA).
3. The composition according to claim 1 wherein it contains 0.1 to 10% DNA.
4. The composition according to claim 1 further comprising an active ingredient.
5. The composition according to claim 4 wherein the active ingredient is selected from a group consisting of vitamin E, vitamin C, borage oil, argan oil and a ginkgo biloba extract.
6. The composition according to claim 4 wherein the composition contains 0.1 to 3% by weight of the said associated active ingredient.
7. The composition according to claim 1 further comprising one or more vehicles appropriate for use in cosmetology.
8. A process for the preparation of a composition containing a liposome gel comprising the following steps:
1) Preparing a lipid phase comprising a solution of amphiphilic liquids in an organic solvent;
2) Adding the lipid phase with gentle stirring, to a solution of thermal water containing a said associated active ingredient of hydrophilic;
3) Evaporating under reduced pressure the liquid phase and thermal water to obtain a suspension of desired liposome concentration; and
4) Introducing DNA into the suspension with gentle stirring.
9. The composition according to claim 4 wherein the associated active ingredient is an antibacterial agent.
10. The composition according to claim 9 wherein the antibacterial agent is selected from a group consisting of phenonip, EDTA, benzoic acid, butyl para-hydrobenzoate and sorbic acid.
11. The method according to claim 8 further comprising the addition of an active ingredient of lipophilic nature in step 1.
12. The method according to claim 8 wherein the organic solvent in step 1 is ethanol.
13. The method according to claim 8 further comprising the addition of an active ingredient of hydrophilic nature in step 2.
US08/066,111 1990-10-17 1991-10-16 Liposomes of thermal waters stabilized in a DNA gel Expired - Lifetime US5376379A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9012811 1990-10-17
FR9012811A FR2668063A1 (en) 1990-10-17 1990-10-17 LIPOSOMES OF THERMAL WATER STABILIZED IN A DNA GEL.
PCT/FR1991/000805 WO1992006666A1 (en) 1990-10-17 1991-10-16 Dna gel stabilized thermal water liposomes

Publications (1)

Publication Number Publication Date
US5376379A true US5376379A (en) 1994-12-27

Family

ID=9401303

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/066,111 Expired - Lifetime US5376379A (en) 1990-10-17 1991-10-16 Liposomes of thermal waters stabilized in a DNA gel

Country Status (9)

Country Link
US (1) US5376379A (en)
EP (1) EP0554343B1 (en)
JP (1) JP3230239B2 (en)
AT (1) ATE107850T1 (en)
DE (1) DE69102707T2 (en)
DK (1) DK0554343T3 (en)
ES (1) ES2059161T3 (en)
FR (1) FR2668063A1 (en)
WO (1) WO1992006666A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690946A (en) * 1994-07-22 1997-11-25 L'oreal Cosmetic and/or dermatological composition containing thermal spring water or mineral water and an active agent, in order to combat acne or aging
US6048546A (en) * 1997-07-31 2000-04-11 Sandia Corporation Immobilized lipid-bilayer materials
RU2161974C1 (en) * 2000-01-20 2001-01-20 Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии" Treatment-and-prophylactic agent for skin care
US6224871B1 (en) * 1998-03-11 2001-05-01 Reliv International, Inc. Dietary supplement for nutritionally promoting healthy joint function
US6372791B1 (en) 2000-06-29 2002-04-16 Johnson & Johnson Consumer Companies, Inc. Method of promoting skin cell metabolism
US6432424B1 (en) 2000-06-29 2002-08-13 Johnson & Johnson Consumer Companies, Inc. Cosmetic compositions containing creatine, carnitine, and/or pyruvic acid
US6475516B2 (en) * 1996-04-12 2002-11-05 Dicosmo Frank Drug delivery via therapeutic hydrogels
US6630175B1 (en) 2000-06-29 2003-10-07 Johnson & Johnson Consumer Companies, Inc. Method of reducing eye irritation
US6649176B1 (en) 2000-06-29 2003-11-18 Johnson & Johnson Consumer Companies, Inc. Compositions containing mineral water
US20040061350A1 (en) * 2002-09-10 2004-04-01 Naoki Yoshida Windscreen mounting structure for a motorcycle
US20040121019A1 (en) * 2002-12-24 2004-06-24 Coletica Particles comprising a biopolymer which is degradable under the effect of an electromagnetic wave as emitted by a solar radiation
US20100003315A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
US20100003314A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and composition for the treatment of skin conditions
WO2010091827A2 (en) 2009-02-12 2010-08-19 Hubert Lengheim Cosmetic formulation for skin care
US20100310673A1 (en) * 2008-03-31 2010-12-09 Morinaga Milk Industry Co., Ltd. Substance and composition both capable of imparting heat resistance
GB2474041A (en) * 2009-10-02 2011-04-06 Omorovicza Cosmetics Ltd Cosmetic composition comprising thermal mineral water
DE10203923B4 (en) * 2002-01-31 2011-06-01 Klinipharm Gmbh A method for increasing the water solubility of lipophilic active ingredients, preparation of highly concentrated aqueous compositions of these active ingredients, such products and their use
US20140193524A1 (en) * 2008-07-02 2014-07-10 Kenneth L. Willeford Method and composition for the treatment of skin conditions

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687913A1 (en) * 1992-02-28 1993-09-03 Oreal COMPOSITION FOR TOPICAL TREATMENT CONTAINING LIPID VESICLES ENCAPSULATING AT LEAST MINERAL WATER.
FR2704390B1 (en) * 1993-04-29 1995-06-02 Boiron Nutritional supplement absorbable per-bone intended to improve the skin.
DE4334600C2 (en) * 1993-10-11 1997-07-03 Hgb Pharma Service Gmbh Topical formulation of a solubilized Ginkgo biloba extract
FR2712492B1 (en) * 1993-11-16 1996-02-09 Fabre Pierre Cosmetique Cosmetic compositions based on thermal waters and their preparation process.
FR2738742B1 (en) * 1995-09-19 1997-11-14 Oreal USE OF AT LEAST ONE VICHY THERMAL WATER AS AN ANTAGONIST OF SUBSTANCE P
ATE192334T1 (en) 1995-11-09 2000-05-15 Microbiological Res Authority MICRO-ENCAPSULED DNA FOR VACCINATION AND GENE THERAPY
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
EP1170002A1 (en) * 2000-06-29 2002-01-09 JOHNSON &amp; JOHNSON CONSUMER COMPANIES, INC. Method of reducing the loss of skin elasticity and firmness
JP4758915B2 (en) * 2004-08-06 2011-08-31 バイオスペクトラム，インコーポレイテッド Multilamellar liposome and production method thereof
FR2985662B1 (en) * 2012-01-16 2014-10-17 Argentum Holding Sarl DERMO-COSMETIC COMPOSITIONS BASED ON A SYNERGISTIC COLLOIDAL SILVER AND DESOXYRIBONUCLEIC ACID ASSOCIATION

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2511243A1 (en) * 1980-12-02 1983-02-18 Geskis Denise Cosmetic contg. polymerised salmon sperm DNA - esp. useful in sunscreen formulations
FR2609393A1 (en) * 1988-02-23 1988-07-15 Serobiologiques Lab Sa Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared
JPH0361859A (en) * 1989-07-31 1991-03-18 Nitsusui Seiyaku Kk Liposome dispersion fluid stabilizer
US5244672A (en) * 1988-12-02 1993-09-14 Coletica Composition containing liposomes stabilized by a stabilizing support based on atelocollagen and glycosaminoglycans

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213572B (en) * 1986-12-19 1989-12-20 Chimico Farmaceutico E Granell METHOD FOR AN EFFECTIVE MOISTURIZING TREATMENT OF THE SKIN, PARTICULARLY FOR COSMETIC FIELD APPLICATION.
FR2634375B3 (en) * 1988-06-30 1991-07-05 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF DISPERSIBLE COLLOIDAL LIPID AMPHIPHILIC SYSTEMS IN THE FORM OF SUBMICRON LIPOSOMES
FR2622104B1 (en) * 1987-10-22 1990-03-30 Bioetica Sa METHOD FOR STABILIZING HYDRATED LIPID LAMELLAR PHASES, FOR EXAMPLE. OF LIPOSOMES, COMPOSITION OF HYDRATED LIPID LAMELLAR PHASES, EG. LIPOSOMES, STABILIZED BY THE USE OF A STABILIZING MEDIUM BASED ON ATELOCOLLAGEN AND GLYCOSAMINOGLYCANS AND USE IN PHARMACY OR COSMETOLOGY

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2511243A1 (en) * 1980-12-02 1983-02-18 Geskis Denise Cosmetic contg. polymerised salmon sperm DNA - esp. useful in sunscreen formulations
FR2609393A1 (en) * 1988-02-23 1988-07-15 Serobiologiques Lab Sa Composition which is useful, in particular, as a base material for the preparation of pharmaceutical, in particular dermatological and/or cosmetic, compositions, comprising a nitrogenous substance, in particular amino acids, oligo- or polypeptides, proteins, and their derivatives, and pharmaceutical or cosmetic composition thus prepared
US5244672A (en) * 1988-12-02 1993-09-14 Coletica Composition containing liposomes stabilized by a stabilizing support based on atelocollagen and glycosaminoglycans
JPH0361859A (en) * 1989-07-31 1991-03-18 Nitsusui Seiyaku Kk Liposome dispersion fluid stabilizer

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690946A (en) * 1994-07-22 1997-11-25 L'oreal Cosmetic and/or dermatological composition containing thermal spring water or mineral water and an active agent, in order to combat acne or aging
US5997885A (en) * 1994-07-22 1999-12-07 L'oreal Cosmetic and/or dermatological composition containing thermal spring water or mineral water and an active agent, in order to combat acne or aging
US6475516B2 (en) * 1996-04-12 2002-11-05 Dicosmo Frank Drug delivery via therapeutic hydrogels
US6048546A (en) * 1997-07-31 2000-04-11 Sandia Corporation Immobilized lipid-bilayer materials
US6224871B1 (en) * 1998-03-11 2001-05-01 Reliv International, Inc. Dietary supplement for nutritionally promoting healthy joint function
RU2161974C1 (en) * 2000-01-20 2001-01-20 Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии" Treatment-and-prophylactic agent for skin care
US6372791B1 (en) 2000-06-29 2002-04-16 Johnson & Johnson Consumer Companies, Inc. Method of promoting skin cell metabolism
US6432424B1 (en) 2000-06-29 2002-08-13 Johnson & Johnson Consumer Companies, Inc. Cosmetic compositions containing creatine, carnitine, and/or pyruvic acid
US6630175B1 (en) 2000-06-29 2003-10-07 Johnson & Johnson Consumer Companies, Inc. Method of reducing eye irritation
US6649176B1 (en) 2000-06-29 2003-11-18 Johnson & Johnson Consumer Companies, Inc. Compositions containing mineral water
DE10203923B4 (en) * 2002-01-31 2011-06-01 Klinipharm Gmbh A method for increasing the water solubility of lipophilic active ingredients, preparation of highly concentrated aqueous compositions of these active ingredients, such products and their use
US20040061350A1 (en) * 2002-09-10 2004-04-01 Naoki Yoshida Windscreen mounting structure for a motorcycle
US8957001B2 (en) * 2002-12-24 2015-02-17 Basf Beauty Care Solutions France Sas Particles comprising a biopolymer which is degradable under the effect of an electromagnetic wave as emitted by a solar radiation
US20040121019A1 (en) * 2002-12-24 2004-06-24 Coletica Particles comprising a biopolymer which is degradable under the effect of an electromagnetic wave as emitted by a solar radiation
US20120053058A1 (en) * 2002-12-24 2012-03-01 Isabelle Bonnet Particles comprising a biopolymer which is degradable under the effect of an electromagnetic wave as emitted by a solar radiation
US8420128B2 (en) 2008-03-31 2013-04-16 Morinaga Milk Industry Co., Ltd. Method of imparting heat resistance to lactoferrin
EP2258380A4 (en) * 2008-03-31 2012-05-02 Morinaga Milk Industry Co Ltd SUBSTANCE AND COMPOSITION ALL TWO CAPABLE OF CONFERRING HEAT RESISTANCE
US20100310673A1 (en) * 2008-03-31 2010-12-09 Morinaga Milk Industry Co., Ltd. Substance and composition both capable of imparting heat resistance
EP2140872A3 (en) * 2008-07-02 2013-04-17 Kenneth Willeford Composition for the treatment of skin conditions comprising sea water with additional magnesium
AU2009202493B2 (en) * 2008-07-02 2012-02-02 Willeford, Kenneth L Method and composition for the treatment of skin conditions
US20100003314A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and composition for the treatment of skin conditions
US20140193524A1 (en) * 2008-07-02 2014-07-10 Kenneth L. Willeford Method and composition for the treatment of skin conditions
US20100003315A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
WO2010091827A3 (en) * 2009-02-12 2010-10-28 Hubert Lengheim Cosmetic formulation for skin care
WO2010091827A2 (en) 2009-02-12 2010-08-19 Hubert Lengheim Cosmetic formulation for skin care
GB2474041A (en) * 2009-10-02 2011-04-06 Omorovicza Cosmetics Ltd Cosmetic composition comprising thermal mineral water
US9956161B2 (en) 2009-10-02 2018-05-01 Omorovicza Cosmetics Limited Cosmetic preparations

Also Published As

Publication number Publication date
DE69102707T2 (en) 1995-03-02
WO1992006666A1 (en) 1992-04-30
FR2668063B1 (en) 1994-12-16
ATE107850T1 (en) 1994-07-15
DE69102707D1 (en) 1994-08-04
JPH06502158A (en) 1994-03-10
DK0554343T3 (en) 1994-11-14
ES2059161T3 (en) 1994-11-01
FR2668063A1 (en) 1992-04-24
JP3230239B2 (en) 2001-11-19
EP0554343B1 (en) 1994-06-29
EP0554343A1 (en) 1993-08-11

Similar Documents

Publication Publication Date Title
US5376379A (en) Liposomes of thermal waters stabilized in a DNA gel
US4761288A (en) Multiphase liposomal drug delivery system
US4897269A (en) Administration of drugs with multiphase liposomal delivery system
JP4758915B2 (en) Multilamellar liposome and production method thereof
US5585109A (en) Cosmetic delivery system for salicylic acid and process for preparation of same
CA1339008C (en) Amphotericin b liposome preparation
EP0177223B1 (en) Pharmaceutical multi-phase composition
Gupta et al. Glycerosomes: Advanced Liposomal Drug Delivery System.
KR102164218B1 (en) Multilayer cationic liposome for enhancing the skin penetration and preparation method thereof
TWI236911B (en) Stabilized whitening compositions and methods of preparing same
US6071535A (en) Lipid vesicles formed with alkylammonium fatty acid salts
US20030017183A1 (en) Dermatological suspensions(micro-matrix)
JP5548362B2 (en) Cationic polymer nanocapsules containing oil-soluble active ingredients and cosmetic compositions containing the same
WO2019111415A1 (en) Cationized vesicles and composition thereof
Nagarsenker et al. Preparation, characterization, and evaluation of liposomal dispersions of lidocaine
Kamra et al. Topical liposomal gel: A review
Vohra et al. Nano-Transferosomes of Aloe-Vera and Vitamin-E for Management of Psoriasis: An Archetype in Herbal Drug Technology
Roslan et al. Liposome as transdermal carrier for Labisia pumila and Ficus deltoidea water extracts
US20090196914A1 (en) Liposomal l-carnitine
Patil et al. Ethosome: a versatile tool for novel drug delivery system
El-Assal Proniosomes as nano-carrier for transdermal delivery of atenolol niosomal gel
DE4238779A1 (en) Lyotropic mesophases for pharmaceutical, dermatological or cosmetic use - contains active ingredients from plants e.g. vitamins or proteins such as superoxidedismutase.
Nadaf et al. Novel liposome derived nanoparticulate drug delivery system: fabrication and prospects
Jansen et al. Encapsulation to deliver topical actives
MOURTAS et al. Liposomal gels for vaginal delivery of the microbicide MC-1220: preparation and in vivo vaginal toxicity and pharmacokinetics

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

AS Assignment

Owner name: PIERRE FABRE COSMETIQUE, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FABRE, PIERRE;COUSSE, HENRI;MOUZIN, GILBERT;AND OTHERS;REEL/FRAME:006697/0758

Effective date: 19930521

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12